COMP <GO>
TDG vs TMO // RSI-14 & 200D SMA MOMENTUM
Transdigm Group Incorporated (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: TDG 8
— TMO 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: TMO
LAST: $1,146.81 (-2.47%) • MKT CAP: $65.00B
rsi-technicals
60.4
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
rsi-technicals
62.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TDG VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TDG | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 63.30% | 9.30% | +54.00 | TDG | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.5x | 30.4x | -12.90 | TDG | /valuation <GO> |
| Free Cash Flow Yield | 2.79% | 2.40% | +0.39 | TDG | /fcf-yield <GO> |
| Operating Margin | 47.20% | 17.40% | +29.80 | TDG | /operating-margins <GO> |
| Net Profit Margin | 23.50% | 15.10% | +8.40 | TDG | /net-margins <GO> |
| Revenue Growth (YoY) | 11.20% | 3.90% | +7.30 | TDG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 11.50% | 0.24% | +11.26 | TDG | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.76 | 4.50 | -2.74 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 60.4 | 62.9 | -2.50 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.94 | -0.05 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.1x | 36.3x | -7.20 | TDG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $65.00B | $262.22B | -$197.22B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TDG REV | TMO REV | TDG GROSS % | TMO GROSS % | TDG FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.83B | $44.56B | 60.1% | — | $1.82B | $6.29B |
| FY 2024 | $7.94B | $42.88B | 58.8% | — | $1.88B | $7.27B |
| FY 2023 | $6.58B | $42.86B | — | — | $1.08B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TDG // BETA 0.89
TMO // BETA 0.94